Table 1. Characteristics of study participants in Phase 1.
| Variable | Proportion n (%) |
|---|---|
| Total | 708 |
| Gender | |
| Male | 227 (32.1) |
| Female | 476 (67.2) |
| Unknown | 5 (0.7) |
| Median age (years) [IQR] | 42 [34–50] |
| Median CD4 (cells/mm3) | 297 [170–499] |
| Reason for CD4 testing | |
| Advanced HIV disease screening | 272 (38.4) |
| ART initiation | 267 (37.7) |
| ART monitoring | 98 (13.8) |
| Other | 71 (10.0) |
| Participant morbid conditions§ | |
| TB | 178 (25.1) |
| Malaria | 26 (3.7) |
| Cryptococcal meningitis | 14 (2.0) |
| Toxoplama ghondii | 7 (1.0) |
| Severe bacterial sepsis | 11 (1.6) |
| Other | 152 (21.5) |
| Missing | 320 (45.1) |
Key:
§ Majority of patients were presenting with multiple morbidities. Also, as data was collected prospectively, a significant number of patients had ‘unknown diagnosis’ upon time of initial consultation (i.e time of study patient data collection).